EFPIA embraces "competitiveness check" for pharma legislation

21 March 2023

Drugmakers have welcomed the European Commission’s commitment to a “competitiveness check,” related to the legislative environment in the region.

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has urged the EC to act quickly to deliver a full assessment of proposed pharmaceutical legislation on European competitiveness.

Director general Nathalie Moll said the trade body supported the communication on competitiveness, adding: “For legislation that will shape our health, science, jobs and growth for the next 20 to 30 years, it is deeply concerning that no complete competitiveness check has yet been made.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK